SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Colloton Robert C

(Last)

(First)

(Middle)

821 FOX LANE

(Street)

SAN JOSE

95131

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MICRUS ENDOVASCULAR CORP [ MEND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	VP Global Sales & Marketing

3. Date of Earliest Transaction (Month/Day/Year)
09/27/2010

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/27/2010		D		25	D	⁽¹⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$9.19	09/27/2010		D			16,145	⁽²⁾	05/26/2019	Common Stock	16,145	$14.21⁽²⁾	0	D
Stock Option (Right to Buy)	$11.42	09/27/2010		D			6,042	⁽²⁾	05/14/2018	Common Stock	6,042	$11.98⁽²⁾	0	D
Stock Option (Right to Buy)	$9.19	09/27/2010		D			8,855	⁽²⁾	05/26/2019	Common Stock	8,855	$14.21⁽²⁾	0	D
Stock Option (Right to Buy)	$9.25	09/27/2010		D			40,943	⁽²⁾	01/06/2016	Common Stock	40,943	$14.15⁽²⁾	0	D
Stock Option (Right to Buy)	$21.04	09/27/2010		D			18,077	⁽²⁾	05/29/2017	Common Stock	18,077	$2.36⁽²⁾	0	D
Stock Option (Right to Buy)	$21.04	09/27/2010		D			6,923	⁽²⁾	05/29/2017	Common Stock	6,923	$2.36⁽²⁾	0	D
Stock Option (Right to Buy)	$5.625	09/27/2010		D			57,913	⁽²⁾	02/23/2015	Common Stock	57,913	$17.775⁽²⁾	0	D
Stock Option (Right to Buy)	$5.625	09/27/2010		D			53,197	⁽²⁾	02/23/2015	Common Stock	53,197	$17.775⁽²⁾	0	D
Stock Option (Right to Buy)	$11.42	09/27/2010		D			13,958	⁽²⁾	05/14/2018	Common Stock	13,958	$11.98⁽²⁾	0	D
Stock Option (Right to Buy)	$9.25	09/27/2010		D			9,057	⁽²⁾	01/06/2016	Common Stock	9,057	$14.15⁽²⁾	0	D

Explanation of Responses:

1. Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., each share of common stock held by the reporting person was converted into the right to receive $23.40 in cash, without interest.

2. Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., this stock option was converted into the right to receive an amount in cash per share subject to the stock option equal to the excess of the per share merger consideration of $23.40 over the per share exercise price of such stock option, without interest.

Remarks:

	/s/ Carolyn M. Bruguera, Attorney-in-Fact for Robert C. Colloton	09/28/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.